{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T22:31:57Z","timestamp":1783031517825,"version":"3.54.6"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      Acute myeloid leukemia (AML) presents significant treatment challenges, particularly in refractory or relapsed (R\/R) cases. This study evaluates the efficacy and outcomes of the salvage chemotherapy regimen containing etoposide 100 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      and mitoxantrone 10 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      , both on days 1\u20135 (EM) in non-M3 AML patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>In a retrospective cohort study, data from 2011 to 2021 were analyzed for adult non-M3 AML patients in a tertiary referral center. Patients who underwent EM salvage chemotherapy after induction failure were included. Exclusion criteria were patients who died during induction, remission with induction, or ineligible for salvage chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Out of 449 non-M3 AML patients, 41 (9.1%) received the EM regimen. Of these, 19 (46.3%) showed no response, 5 (12.2%) achieved partial remission (PR), and 17 (41.5%) attained complete remission (CR). The median overall survival (OS) for all patients was 6 months (95% CI 2.3\u20139.6), with 12, 24, and 36-month OS rates of 31%, 23%, and 15%, respectively. Patients achieving CR or PR had significantly better outcomes compared to refractory patients. Patients who did not receive hematopoietic stem cell transplantation (HSCT) had a median OS of 7 months, while it was not reached for those who did undergo HSCT. At 36 months, the OS rate was significantly higher in patients who underwent HSCT than in those who did not (71.4% vs. 8.3%\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The EM regimen offers a potential pathway to remission for R\/R non-M3 AML patients. However, the outcomes are heavily influenced by patient-specific factors and subsequent treatment strategies such as HSCT.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ms9.0000000000004285","type":"journal-article","created":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T14:00:21Z","timestamp":1763042421000},"page":"110-118","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Salvage therapy with etoposide and mitoxantrone in patients with refractory acute myeloid leukemia: a retrospective cohort study"],"prefix":"10.1097","volume":"88","author":[{"given":"Mehrzad","family":"Mirzania","sequence":"first","affiliation":[{"name":"Department of Hematology and Medical Oncology, Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4607-7842","authenticated-orcid":false,"given":"Ahmad","family":"Khajeh-Mehrizi","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2643-749X","authenticated-orcid":false,"given":"Tahereh","family":"Yavari","sequence":"additional","affiliation":[{"name":"Rheumatology Research Center, Shariati Hospital, Tehran University for Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3268-9864","authenticated-orcid":false,"given":"Seyed Reza","family":"Safaei Nodehi","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9245-5840","authenticated-orcid":false,"given":"Kamran","family":"Roudini","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2155-1683","authenticated-orcid":false,"given":"Hamideh","family":"Rashidian","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1361-6205","authenticated-orcid":false,"given":"Khashayar","family":"Danandeh","sequence":"additional","affiliation":[{"name":"Sports Medicine Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6835-9433","authenticated-orcid":false,"given":"Peyman","family":"Tayyari","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,11,14]]},"reference":[{"key":"R1-20260514","doi-asserted-by":"crossref","first-page":"2196482","DOI":"10.1080\/16078454.2023.2196482","article-title":"A review of treatment options employed in relapsed\/refractory AML","volume":"28","author":"Mohamed Jiffry","year":"2023","journal-title":"Hematology"},{"key":"R2-20260514","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41408-021-00425-3","article-title":"Acute myeloid leukemia: current progress and future directions","volume":"11","author":"Kantarjian","year":"2021","journal-title":"Blood Cancer J"},{"key":"R3-20260514","doi-asserted-by":"crossref","first-page":"1306\u201313","DOI":"10.1038\/leu.2017.23","article-title":"Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure","volume":"31","author":"Wattad","year":"2017","journal-title":"Leukemia"},{"key":"R4-20260514","doi-asserted-by":"crossref","first-page":"860\u201391","DOI":"10.1002\/ajh.27625","article-title":"Acute myeloid leukemia: 2025 update on diagnosis, risk-stratification, and management","volume":"100","author":"Shimony","year":"2025","journal-title":"Am J Hematol"},{"key":"R5-20260514","doi-asserted-by":"crossref","first-page":"106300","DOI":"10.1016\/j.leukres.2020.106300","article-title":"Efficacy of mitoxantrone-based salvage therapies in relapsed or refractory acute myeloid leukemia in the mayo clinic cancer center: analysis of survival after \u2018CLAG-M\u2019vs.\u2018MEC.\u2019","volume":"90","author":"Scheckel","year":"2020","journal-title":"Leuk Res"},{"key":"R6-20260514","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3727\/096504016X14586627440156","article-title":"Mitoxantrone and etoposide for the treatment of acute myeloid leukemia patients in first relapse","volume":"24","author":"Im","year":"2016","journal-title":"Oncol Res"},{"key":"R7-20260514","doi-asserted-by":"crossref","first-page":"1115\u201353","DOI":"10.1007\/s00277-018-3304-y","article-title":"Salvage regimens using conventional chemotherapy agents for relapsed\/refractory adult AML patients: a systematic literature review","volume":"97","author":"Meg\u00edas-Vericat","year":"2018","journal-title":"Ann Hematol"},{"key":"R8-20260514","doi-asserted-by":"crossref","first-page":"411\u201316","DOI":"10.1111\/j.1600-0609.1989.tb00328.x","article-title":"Mitoxantrone and etoposide: an effective regimen for refractory or relapsed acute myelogenous leukemia","volume":"43","author":"Lazzarino","year":"1989","journal-title":"Eur J Haematol"},{"key":"R9-20260514","doi-asserted-by":"crossref","DOI":"10.34172\/ipp.2022.27272","article-title":"Evaluation of FLANG versus mitoxantrone and etoposide for the treatment of refractory\/relapsed acute leukemia","author":"Mehrzad","year":"2022","journal-title":"Immunopathol Persa"},{"key":"R10-20260514","article-title":"Cancer chemotherapy","author":"Amjad"},{"key":"R11-20260514","article-title":"STROCSS Group. Revised Strengthening the reporting of cohort, cross-sectional and case-control studies in surgery (STROCSS) Guideline: An update for the age of Artificial Intelligence","volume":"10","author":"Agha","year":"2025","journal-title":"Prem J Sci"},{"key":"R12-20260514","doi-asserted-by":"crossref","first-page":"58\u201374","DOI":"10.1016\/j.bjhh.2016.01.001","article-title":"Guidelines on the treatment of acute myeloid leukemia: associa\u00e7\u00e3o brasileira de hematologia, hemoterapia e terapia celular","volume":"38","author":"Bittencourt","year":"2016","journal-title":"Rev Bras Hematol Hemoter"},{"key":"R13-20260514","doi-asserted-by":"crossref","first-page":"213\u201317","DOI":"10.1200\/JCO.1988.6.2.213","article-title":"Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia\u2013an active and well-tolerated regimen","volume":"6","author":"Ho","year":"1988","journal-title":"J Clin Oncol"},{"key":"R14-20260514","doi-asserted-by":"crossref","first-page":"31\u201341","DOI":"10.1007\/s12288-021-01430-z","article-title":"Outcomes of HIDAC 18 g versus IDAC 9 g in consolidation therapy of acute myeloid leukemia: a retrospective study","volume":"38","author":"Ravikumar","year":"2022","journal-title":"Indian J Hematol Blood Transfus"},{"key":"R15-20260514","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3390\/cancers10060179","article-title":"Allogeneic hematopoietic cell transplantation for older adults with acute myeloid leukemia","volume":"10","author":"Lipof","year":"2018","journal-title":"Cancers (Basel)"},{"key":"R16-20260514","first-page":"424\u201347","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"J Am Society Hematol"},{"key":"R17-20260514","doi-asserted-by":"crossref","first-page":"394\u201396","DOI":"10.1016\/j.leukres.2011.10.027","article-title":"Mitoxantrone and etoposide with or without intermediate dose cytarabine for the treatment of primary induction failure or relapsed acute myeloid leukemia","volume":"36","author":"Trifilio","year":"2012","journal-title":"Leuk Res"},{"key":"R18-20260514","first-page":"1025\u201327","article-title":"Combination therapy with mitoxantrone and etoposide in refractory acute myelogenous leukemia","volume":"70","author":"Ho","year":"1986","journal-title":"Cancer Treat Rep"},{"key":"R19-20260514","first-page":"549\u201352","article-title":"Mitoxantrone, etoposide and intermediate-dose Ara-C (MEC): an effective regimen for poor risk acute myeloid leukemia","volume":"7","author":"Spadea","year":"1993","journal-title":"Leukemia"},{"key":"R20-20260514","doi-asserted-by":"crossref","first-page":"e441","DOI":"10.1038\/bcj.2016.50","article-title":"Acute myeloid leukemia: a comprehensive review and 2016 update","volume":"6","author":"De Kouchkovsky","year":"2016","journal-title":"Blood Cancer J"},{"key":"R21-20260514","doi-asserted-by":"crossref","first-page":"101102","DOI":"10.1016\/j.beha.2019.101102","article-title":"Post-remission therapy in acute myeloid leukemia: are we ready for an individualized approach?","volume":"32","author":"Derman","year":"2019","journal-title":"Best Pract Res Clin Haematol"},{"key":"R23-20260514","doi-asserted-by":"crossref","first-page":"123\u201332","DOI":"10.1007\/BF00174159","article-title":"Mitoxantrone: an overview of safety and toxicity","volume":"3","author":"Posner","year":"1985","journal-title":"Invest New Drugs"},{"key":"R24-20260514","article-title":"Common Terminology Criteria for Adverse Events (CTCAE) v5.0"}],"container-title":["Annals of Medicine &amp; Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MS9.0000000000004285","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T09:07:09Z","timestamp":1778749629000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MS9.0000000000004285"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ms9.0000000000004285","relation":{},"ISSN":["2049-0801"],"issn-type":[{"value":"2049-0801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,14]]},"assertion":[{"value":"2025-05-21","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-29","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}